Core Viewpoint - The company, Shanghai Junshi Biosciences Co., Ltd. (复宏汉霖), has successfully launched its self-developed anti-PD-1 monoclonal antibody, Hanshuo, in India, marking a significant milestone in its global expansion strategy [1]. Group 1 - Hanshuo is the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) [1]. - The drug has been approved for marketing in nearly 40 countries and regions, including China, the UK, Germany, India, Indonesia, and Singapore [1]. - In India, Hanshuo received approval from the Central Drugs Standard Control Organization in June 2025, becoming the first anti-PD-1 monoclonal antibody approved for this indication [1]. Group 2 - The company's partner, Intas, will be responsible for the commercialization of Hanshuo in India, aiming to benefit more patients [1]. - The president of the company, Huang Wei, emphasized the strategic vision of benefiting global patients and highlighted the efficient operation of their global supply system [1]. - Since its launch, Hanshuo has benefited over 110,000 patients worldwide, expanding the accessibility of global immunotherapy [1].
复宏汉霖：汉斯状在印度获批上市并已完成首批发货